rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Xenetic Biosciences, Inc.

XBIO · Nasdaq

Health CareBiotechnologyNot moving yet

XBIO stood above a rising 150-day average in 14 of the last 52 weekly readings, and has been out of that trend for the last 6 weeks. It is 32.8% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−12 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 6
Industry in uptrend
18% -12 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
7 (+2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 14 of 52 weeks.

22 Apr – 21 Oct
16%27%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders7+2 on the quarter
New · exited2 · 0
Reported value$435K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 2026117,440$342K-20,000−14.6%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202617,423$51K-4,018−18.7%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 202612,681$37K+5,950+88.4%
SBI Securities Co., Ltd.new · filed 23 Jul 20261,000$2,910+1,000
Tower Research Capital LLC (TRC)reduced · filed 11 Aug 2026696$2,025-110−13.6%
MORGAN STANLEYnew · filed 13 Aug 2026150$437+150
Darwin Wealth Management, LLCunchanged · filed 21 Jul 20262$500.0%
30 Jun 2023 – 30 Jun 2026
4812Jun 23Mar 24Dec 24Sep 25Jun 26

Everyone who traded it

James F. Parslow Company insiderInterim CEO and CFO · last 21 Apr 20260 · 0
Alexey Andreevich Vinogradov Company insiderDirector · last 31 Dec 20250 · 0
Firdaus J. Dastoor Company insiderDirector · last 31 Dec 20250 · 0
Grigory G. Borisenko Company insiderDirector · last 31 Dec 20250 · 0
Roger D. Kornberg Company insiderDirector · last 31 Dec 20250 · 0
Curtis Lockshin Company insiderChief Sciencific Officer · last 11 Dec 20230 · 0
Jeffrey F. Eisenberg Company insiderChief Executive Officer · last 11 Dec 20230 · 0
Adam Logal Company insiderDirector · last 6 Dec 20230 · 0
James Eric Callaway Company insiderDirector · last 6 Dec 20230 · 0
Moshe Mizrahy Company insiderDirector · last 6 Dec 20230 · 0
Dmitry Genkin Company insiderDirector · last 19 Jul 20190 · 0
Darlene M. Deptula-Hicks Company insiderDirector · last 20 Dec 20160 · 0

Same industry

MRNA ModernaLeading+168%
ENTX Entera BioLeading+53%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 2025-95.2%
Return on capital employedFY 2025 · to 31 Dec 2025-38.3%
Interest coverFY 2025 · to 31 Dec 2025-19.15×
Research spendFY 2025 · to 31 Dec 2025103%
Share count trendFY 2025 · to 6 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$7.9M

Analyst forecasts

No analyst forecasts yet.